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Cancer-associated fibroblasts—heroes or villains?
Krystyna A. Gieniec1,2, Lisa M. Butler1,2, Daniel L. Worthley2 and Susan L. Woods1,2
Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving
tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by
sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely
appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated
that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or
inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So,
while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality
and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to
reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically
targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment
strategies in order to provide a case for future, rational therapies.
British Journal of Cancer (2019) 121:293–302; https://doi.org/10.1038/s41416-019-0509-3
BACKGROUND
Fibroblasts are non-specialised cells of the connective tissue
stroma that support tissue function and homoeostasis by
regulating the extracellular matrix (ECM), inflammation and
epithelial cell proliferation and differentiation (reviewed in ref. 1)
They are predominantly quiescent, only transiently acquiring
activity during periods of tissue remodelling and repair. Activated
fibroblasts will then either apoptose or revert back to a dormant
state once their function becomes redundant; otherwise, patho-
logical conditions such as tissue fibrosis and chronic inflammation
can arise.2 This chronic tissue repair response has been implicated
in the progression to cancer,3 and tumours can therefore be
considered as ‘wounds that do not heal’.4 Distinct, activated
fibroblasts that surround tumours are termed cancer-associated
fibroblasts (CAFs) and they, along with other elements of the
tumour microenvironment, can indulge in reciprocal dialogues
with the neoplastic epithelial cells to maximise tumour fitness.
The role of CAFs in cancer has risen to prominence, with genes
positively associated with colorectal cancer (CRC) recurrence and
poor prognosis predominantly found to be upregulated within the
CAF population, not in tumour cells.5,6 Furthermore, when CRC
was classified into four distinct consensus molecular subtypes
(CMSs), it was revealed that CMS4, with over-representation of the
stromal signature, was associated with more aggressive tumour
stages and worse overall survival than other subtypes.7 CAFs have
subsequently been implicated in different stages of cancer
development, from primary growth to secondary colonisation at
metastatic sites, in different cancer types. However, a number of
contradictory studies have proposed an anti-tumour role for CAFs,
as ablation of CAFs expressing specific markers, such as α-smooth
muscle actin (α-SMA), or inhibition of signalling pathways
proposed to be important in CAF-mediated tumorigenesis (such
as hedgehog, Hh) actually resulted in more aggressive pancreatic
ductal adenocarcinoma (PDAC).8,9 While studies involving tumour-
suppressive CAF populations are in the minority, they clearly
demonstrate the need to more fully understand the role of
discrete and possibly opposing CAF subpopulations in order to
effectively target tumours.
The identification of markers that define CAF subsets is in its
infancy, and this has hindered the study of specific CAFs. Two
commonly used molecular CAF markers are α-SMA and fibroblast
activation protein (FAP), but these markers do not perfectly
demarcate precisely the same population of cells.10 Many other
markers for CAFs have been identified, such as vimentin,
fibroblast-specific protein-1 (FSP1), and platelet-derived growth
factor receptor-β (PDGFRβ),11 which are discussed below. It has
become apparent that CAFs form a large heterogeneous
population of cells expressing a wide array of molecular markers,
which are not necessarily unique to fibroblasts. It might be that
particular CAF subsets have a tendency for tumour promotion or
suppression, perhaps determined by tumour type and location,
but the biological programmes influencing these phenotypes
currently remain unknown. In order to successfully use CAFs as a
form of cancer treatment, CAF complexity must be resolved such
that specific pro-tumorigenic subtypes can be inhibited or
converted back into a quiescent state.
This review will provide an overview of our current knowledge
of the pro- and anti-tumour roles of CAFs in various tumour
entities and the implications for these findings on cancer
treatment.
THE TUMOUR-PROMOTING CAF PHENOTYPE
The primary role of activated fibroblasts is to remodel and
regenerate tissues, which they do under normal circumstances in
a highly regulated manner. However, this function can be hijacked
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and enhanced in cancer, generating misregulated, tumour-
promoting CAFs. As will be discussed below, CAFs can indirectly
support tumorigenesis by encouraging an oxygen-rich, immuno-
suppressive and pro-inflammatory microenvironment. In addition,
CAFs are capable of directly supporting tumour growth, invasion
and metastasis.
CAFs encourage the development of a tumour-promoting stroma
Although CAFs are the predominant cell type in the tumour
stroma, many other stromal cells contribute to carcinogenesis.
These include pro-inflammatory, immunosuppressive and
endothelial cells, which can be recruited or influenced by CAFs
via a wide array of CAF-derived factors.
Multiple studies have emphasised the tumour-promoting role
of inflammatory cells, from their production of many pro-tumour
factors to their mutagenic involvement in tumour evolution.12
CAFs can adopt a pro-inflammatory gene signature at an early
stage in cancer development, induced by tumour-derived
interleukin (IL)-1β and, as such, themselves mediate this tumour-
enhancing inflammation.13 CAFs can additionally be involved in
tumour immune evasion, inducing an immune-suppressive
microenvironment to facilitate tumour escape from anti-tumour
immune surveillance. When FAP+ stroma was specifically ablated
using diphtheria toxin in genetically modified Lewis lung cancer
(LCC) mice, cytotoxic T-cell activity was restored and rapid tumour
necrosis resulted.14 Combining this ablation with the chemother-
apeutic agent, doxorubicin, resulted in a reduced infiltration of
immune-suppressor cells such as T-regulatory (Treg) cells and
further activated the anti-tumour immune response.15 CAFs can
directly deactivate the immune system, with some CAF subsets
shown to express the negative co-regulatory immune signals,
programmed death-ligand (PD-L)1 and PD-L2 or secrete immune-
suppressive factors, such as prostaglandin E2 (PGE2), to directly
reduce the activation of T and natural killer cells.2,16 The CAF-rich
peritumoural stroma can also physically prevent the immune
system from effectively interacting with the tumour. This
phenomenon of immune exclusion from tumours has been linked
to the lack of patient response to PD-L1 blockade in many cancers,
including metastatic urothelial cancer, and it is associated with a
signature of transforming growth factor-β (TGF-β) signalling in
fibroblasts,17 which is known to activate fibroblasts and induce the
dense stromal reaction. When mouse models of immune-excluded
breast or metastatic CRC were co-treated with TGF-β and PD-L1
inhibitors, the expression of matrix-remodelling factors in CAFs
was reduced and T cells were then able to penetrate both primary
and metastatic tumour masses to cause regression.17,18 However,
the consequences of attempts to manipulate the immune system
for cancer treatment are not always predictable due to the
complex interplay between different cell types in the tumour
microenvironment, including fibroblasts. For example, use of a
colony-stimulating factor 1 receptor (CSF1R) inhibitor for targeting
pro-tumour, tumour-associated macrophages in mouse models of
LLC and melanoma resulted in the enhanced recruitment of
polymorphonuclear myeloid-derived suppressor cells (PMN-
MDSC). The block in CSF1 signalling caused CAFs to secrete the
PMN-MDSC chemokine, C–X–C Motif Chemokine Ligand 1 (Cxc11);
CAFs were therefore able to neutralise the anti-tumour effect of
the CSF1R inhibitor. Tumours were reduced when tumour-bearing
mice were treated with both the CSF1R inhibitor and a C–X–C
Motif Chemokine Receptor 2 (CXCR2) antagonist (to prevent PMN-
MDSC migration), and tumours were completely blocked when a
PD-1 antibody was added to this combination.19
CAFs can respond to hypoxia by upregulating hypoxia-induced
angiogenesis regulator (HIAR), which in turn increases CAF motility
and secretion of vascular endothelial growth factor A (VEGFA).20
This induces angiogenesis to improve tumour oxygenation,
nutrient flow and waste removal, and the resultant decline in
hypoxia stimulates further CAF activation.21 CAFs can also be
influenced to stimulate a vessel-rich environment by tumour cells.
As an example, hepatocellular carcinoma (HCC)-derived exosomal
miRNA-21 activates hepatic stellate cells into CAFs by blocking
PTEN, causing the CAFs to upregulate angiogenic cytokines
including VEGF and increasing vessel density in HCC patients.22
CAFs improve tumour energy synthesis
There are many ways in which CAFs can increase the net energy
production of tumours, fuelling growth. The ‘reverse Warburg
effect’ was recently termed23 to define the phenomenon whereby
CAFs undergo autophagy and mitophagy, resulting in aerobic
glycolysis and the release of energy-rich metabolites that are then
absorbed by cancer cells to enter the tricarboxylic acid (TCA) cycle.
This upregulates tumour mitochondrial oxidative phosphorylation,
improving ATP production.24 In addition, the ketones and lactate
produced as the end products of fibroblastic glycolysis have been
shown to promote the growth and metastasis of breast cancer in
an immunodeficient mouse model,25 by increasing the transcrip-
tional profile of genes associated with ‘stemness’ in cancer cell
lines. This suggests a link between metabolism and cancer stem
cells (CSCs, see below), which could potentially be severed using
oxidative mitochondrial metabolism inhibitors, such as metfor-
min.24 Patient-derived lymphoma CAFs have also been shown to
secrete significant amounts of pyruvate, fuelling lymphoma
tumours via the reverse Warburg effect.26 Patient-derived prostate
cancer CAFs can assist nutrient-deprived prostate and pancreatic
cancer cell lines, via secretion of exosomes containing intact
metabolites, including amino acids and TCA-cycle intermediates,
allowing the tumour cells to continue growing rapidly.27 Interest-
ingly, tumours can enhance their own survival by secreting
exosomes that alter CAF metabolism. In one study, breast-cancer-
secreted exosomes containing miR-105 reprogrammed CAFs by
activating MYC signalling. This imbued the CAFs with the capacity
to enhance glucose metabolism when nutrients were sufficient, or
detoxify metabolic wastes into energy-rich metabolites when
nutrients were scarce, thus ensuring the tumour remained
sufficiently energised for sustained growth.28
ECM remodelling and tumour invasion
The ECM is a dynamic scaffold of glycosaminoglycans and
proteins that functions as a cell-docking station and facilitates
cell communication, differentiation, adhesion and movement. It is
constantly being degraded and synthesised by fibroblasts in a
regulated response to changing tissue conditions; degradation is
facilitated by matrix metalloproteinases (MMPs) and synthesis is
associated with the increased production of proteins, such as
collagen.29 The ECM also functions as a biological repository,
sequestering a wide range of growth factors and cytokines.30 CAFs
perpetually remodel the ECM, and the degradation of ECM
molecules by CAF-generated MMPs not only releases sequestered
proteins to create a self-sustaining feed-forward loop of CAF
activation and ECM remodelling but also creates new molecule
fragments with potential pro-migratory and pro-angiogenic
roles.31,32 Moreover, ECM degradation physically frees up space
for proliferating and migrating tumour cells. The net outcome is
accelerated cancer progression. CAFs additionally stimulate
constitutive collagen cross-linking; they are the primary source
of the cross-linking inducer lysyl oxidase (LOX) in mouse
mammary cancer,33 and LOX inhibition in a mouse breast cancer
model led to a decline in fibrosis, tumour invasion and
metastasis.34 CAF-derived FAP organises these cross-linked fibres
into parallel orientations through its serine protease activity,
forming stiff ‘migration highways’ that enhance the directionality
and velocity of pancreatic cancer cells during invasion via
activation of the β1-integrin/FAK signalling pathway; without
FAP, the ECM remains disorganised and invasion is impeded.35
Lung cancer cells can also adhere to CAFs via integrin α5β1 and
quickly migrate along the long fibroblast protrusions, acquiring
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invasive potential in three-dimensional collagen matrix.36 In
addition, CAFs can directly adhere to the skin and squamous cell
carcinoma (SCC) cells, inducing ECM tracks ahead to further
accelerate invasion.37,38
CAFs, cancer stemness and metastasis
CAFs are suggested to play a role in the induction and
maintenance of a small population of tumorigenic cells that are
capable of self-renewal and multilineage differentiation. These
cells, termed CSCs, have a crucial role in cancer initiation, with one
CSC capable of giving rise to an entire tumour.39 CSCs are
predominantly dormant so they are naturally resistant to anti-
proliferative chemotherapy and therefore difficult to eradicate,
and might be responsible for relapse years after initial treatment.40
CAF-derived chemokine (CC motif) ligand 2 (CCL2), IL-6, hepato-
cyte growth factor (HGF), osteopontin (OPN) and stromal cell-
derived factor 1 (SDF-1) each independently induce the CSC
phenotype in epithelial cells.41–43
CAFs can enhance cancer stemness by inducing an epithelial-to-
mesenchymal transition (EMT) programme in cancer cells, as
described in a mouse model of human prostate cancer.44 EMT is
associated with increased motility of cancer cells, with loss of
cell–cell adhesion and polarity,45 and increased resistance to
therapy. IL-6 is one example of a CAF-derived factor that induces
EMT in oesophageal cancer, and IL-6 inhibition restored sensitivity
of patient-derived oesophageal cancer organoids to chemother-
apy and radiotherapy.46 During EMT, there is also evidence of a
reversion to the epithelial phenotype (mesenchymal-to-epithelial
transition, MET), allowing metastatic outgrowth (discussed in
ref. 47) CAFs are able to accompany disseminated tumour cells in
the circulation, providing survival cues and an early growth
advantage at the metastatic site; partial depletion of CAFs at this
stage significantly decreases the number of successful lung
metastases in a mouse model.48 In serous ovarian cancer, this
phenomenon is a feature of high-grade tumours, where ascetic
tumour cells marked by integrin α-5 (ITGA5) expression are prone
to forming spheroids with CAFs. When CAFs were pre-treated with
imatinib to inhibit PDGFR signalling, mice with ovarian cancer had
reduced peritoneal colonisation and improved survival.49 Infiltrat-
ing tumour cells can also secrete extracellular vesicles containing
TGF-β, educating the foreign niche to resemble the primary
microenvironment. The activated tissue-resident fibroblasts then
express factors to promote epithelial colonisation (MET) and
proliferation, initiating secondary tumorigenesis.50–52
Tumour-promoting CAFs are therefore at least partly respon-
sible for the acquisition of proliferative, pro-inflammatory,
immune-suppressive, angiogenic, pro-invasive and pro-
metastatic environments that are required for aggressive tumor-
igenesis (Fig. 1).
THE TUMOUR-SUPPRESSING CAF PHENOTYPE
Despite the overwhelming evidence indicating that CAFs have a
tumour-promoting role, there are studies suggesting that these
cells, along with normal fibroblasts, are involved in tumour
suppression. Whether these fibroblast subtypes are normal
fibroblasts that are resistant to conversion into CAFs, or distinct
anti-tumour CAF subpopulations, remain unknown (Fig. 1).
The notion that normal cell types have tumour-suppressing
properties was demonstrated by injecting a teratoma cell line into
an early mouse embryo; the resulting postnatal animals were
derived from both host and transplanted tumour cells, but the
tumorigenic phenotype had somehow been suppressed so that
normal development ensued.53 Normal, resting fibroblasts were
suggested to be the tumour-suppressing cell type, as they were
shown to restrain the growth of transformed baby hamster kidney
cells in vitro54 and transformed keratinocytes in vivo.55 Another
in vivo study showed that PDGFRα+ CAFs isolated from a PDAC
mouse model stimulated subcutaneous PDAC tumour growth in
mice by 76%, while normal pancreatic fibroblasts inhibited tumour
growth by 65%.56 Tumour growth-suppressive factors, such as
whey acidic protein four-disulphide core domain 1 (WFDC1), were
highly expressed in resting fibroblasts but downregulated in
CAFs,57 suggesting that dormant fibroblasts might indeed
suppress tumorigenesis. Resting fibroblasts at metastatic sites
can also impede colonisation, as normal bone marrow stroma was
shown to induce quiescence in infiltrating breast cancer cells via
the gap junction-mediated transfer of several miRNAs targeting
CXCL12.58
Studies have also uncovered the presence of tumour-
suppressing fibroblasts in established tumours. PDAC is notorious
for its large fibrotic tumour response, with the majority of tumour
volume being composed of α-SMA+ fibroblasts.8 Depleting these
fibroblasts was hypothesised to reduce PDAC aggression, but
clinical studies relying on this strategy revealed accelerated
disease progression.59 Upon further investigation in mice, it was
confirmed that deletion of α-SMA+ fibroblasts induced invasive
tumours that showed enhanced EMT and increased numbers of
CSCs, and resulted in reduced survival. This outcome was primarily
due to a decline in immune surveillance and increased infiltration
of Treg cells. The fibrotic response associated with PDAC is
therefore a host defence mechanism against tumour invasion.8
Unexpected results were also seen with alteration of Hh signalling
in CAFs. It has been shown that tumour-derived sonic hedgehog
(Shh) activates smoothened (SMO) in fibroblasts, which activates
the fibroblasts and consequently promotes PDAC desmoplasia.60
When Hh signalling was inhibited in CAFs in a PDAC mouse model
using the drug IPI-926, the tumours became transiently vascu-
larised and delivery of the chemotherapeutic agent gemcitabine
was enhanced, increasing mouse survival. This study demon-
strates another example of how CAFs can impact tumour
chemoresistance, as the desmoplastic response causes poor
intratumoural vascularity and consequently inefficient drug
delivery.61 Thus, naturally, it was hypothesised that continued
research into Hh-signalling inhibition would be therapeutically
advantageous. This was not always the case, as deletion of Shh
enhanced disease progression and reduced CAF content in a
PDAC model,9 and activating Hh signalling in fibroblasts markedly
reduced tumour load and disease progression in a colon cancer
model.62 Hh-signalling CAFs therefore appear to act as both
tumour promoters and tumour suppressors, with the specific
factors that predict this behaviour across multiple cancer types
remaining unknown. Interest surrounding serum amyloid A (Saa3)
expression in mouse Pdgfrα+ CAFs has also recently come into
light, as Pdgfrα+Saa3+ CAFs were shown to stimulate PDAC
growth in an orthotopic mouse model while Pdgfrα+Saa3− CAFs
inhibited growth.56 Inhibiting Saa3 could therefore result in an
abundance of anti-tumour CAFs, but the initial findings of this
study await further validation as to their suitability as a therapeutic
target for PDAC. Interestingly, the phenomenon of CAF-induced
cancer regression was demonstrated in a recent study, whereby
CAFs were shown to restore lung SCC spheroids from a dysplastic
to hyperplastic state through the suppression of high epithelial
Sox2 activity. As such, CAFs may have the ability to override cell
intrinsic oncogenic changes and determine the extent of disease
progression.63
There is a growing body of evidence suggesting that cancer
cells influence whether or not fibroblasts suppress tumour growth.
In the normal setting, stromal cells express TGF-β inhibitors
(reviewed in ref. 64) and low expression of one such fibroblast-
derived inhibitor, asporin, is correlated with poor survival in breast
cancer patients. However, asporin expression appears to be
influenced by the tumour’s genetic subtype, suggesting that the
level of fibroblast-induced tumour suppression can be partly
determined by the tumour itself.65 Likewise, breast tumours can
downregulate the roundabout homologue 1 (Robo1) receptor to
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stop the tumour-suppressive effects of its fibroblast-derived
ligand, slit homologue 2 (SLIT2), which inhibits proliferative
β-catenin signalling. This change in expression is associated with
poor prognosis.66,67
The tumour-suppressive phenotype of fibroblasts and CAFs is
therefore dependent on the factors they produce, which remain
largely uncharacterised. Successful tumours must then be able to
evolve mechanisms to control, evade or overcome fibroblast-
induced suppression.
THERAPEUTIC IMPLICATIONS
Because cancer is a complex, dynamic and adaptive ecosystem
reinforced by genetic diversity and epigenetic plasticity, the rapid
emergence of drug resistance is problematic for many patients.
Consequently, there is a need to investigate therapies that are not
necessarily directed at the tumour cells themselves and, as such,
CAFs provide an attractive target: they are genetically stable and
consequently less likely than tumour cells to acquire therapeutic
resistance, and their presence across different cancer types entices
a broad applicability of effective therapies. Some studies have
examined the effect of ablating the prominent CAF subtypes on
carcinogenesis: deletion of FAP-expressing fibroblasts induced
rapid tumour necrosis in LLC14 and impeded metastasis in PDAC,68
whereas elimination of α-SMA fibroblasts enhanced tumorigenesis
in both mouse and clinical models.8,59 CAF-directed therapy
should therefore be designed against specific pro-tumour factors
or functions with the aim of preventing CAF function or activation,
or reprogramming CAFs back into a normal, resting phenotype.
Targeting CAFs as a method of cancer therapy
FAP has been the focus of many CAF-directed preclinical and
clinical cancer studies. A DNA vaccine directed against FAP was
shown to significantly suppress primary and secondary tumours in
a murine colon cancer model by upregulating cytotoxic T-cell-
mediated killing, increasing animal survival.69 Tumour angiogen-
esis was also suppressed following depletion of FAP+ CAFs via
FAP-targeted chimeric antigen receptor (CAR) T cells, with
resultant murine pancreatic tumour retardation.70 The enzymatic
activity of FAP has also been inhibited using the drug PT-100,
which attenuated tumour growth in many mouse models,71 but
showed minimal activity in phase 2 trials of patients with
metastatic CRC.72 The humanised anti-FAP antibody, sibrotuzu-
mab, also showed no beneficial effect in phase 2 trials for
metastatic CRC.73 In both of these trials, the patients were heavily
pre-treated and could therefore represent a refractory patient
population. It is also hypothesised that the biological effects of
FAP may be more prominent in smaller tumours or earlier stages
of CRC, not in late-stage metastasis. Other CAF subtypes, namely
CD10+GPR77+ and IL-7+ CAFs, have been targeted pre-clinically,
resulting in impaired tumour stemness and growth with restored
chemosensitivity in breast cancer patient-derived xenografts
(PDXs) and cell lines, respectively.74,75 Intriguingly, CD10+GPR77+
CAFs directly conveyed a chemo-resistant phenotype on breast
cancer cells in co-culture, co-transplant and PDX models through
the secretion of factors such as IL-6 and the upregulation of the
multidrug-resistance transporter ABCG2.74 The SOM230 analogue,
Pasireotide, has been used in mouse models of PDAC to prevent
IL-6 synthesis (amongst other proteins) through activation of the
somatostatin (sst1) receptor, which then inhibits the mammalian
target of the rapamycin (mTOR)/4E-BP1 pathway. This pathway is
highly activated in α-SMA+ CAFs isolated from human PDAC
resections, and when SOM-230 was administered to mice
engrafted with human PDAC there was a reduction in tumour
growth and chemoresistance to gemcitabine. This drug targets
the pathway in CAFs specifically, as the sst1 receptor is not present
in the epithelium.76 CAF-mediated secretion of IL-6 has also been
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Fig. 1 Roles of CAFs in tumorigenesis. Tumour cells and the surrounding fibroblasts or CAFs communicate to generate a microenvironment
that either promotes or suppresses tumorigenesis. Normal fibroblasts can be stimulated to become CAFs by the tumour, however, the
biological programmes that determine their skew towards a tumour-promoting or tumour-suppressing subtype remain unknown. The
tumour-promoting subtypes aid tumour growth, survival and spread both directly and indirectly, through other tumour-associated stromal
cell types. Both normal fibroblasts and CAFs have been shown to inhibit or retard tumorigenesis, but the mechanisms are relatively unknown
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N-cadherin to E-cadherin in migrating mouse cholangiocarcinoma
cells to diminish their invasion and induce autophagy.77
Additional targets for cancer treatment are MMPs, even though
they are not solely expressed by CAFs, and many different MMP
inhibitors have been developed and tested in phase 1, 2 and 3
clinical trials. Unfortunately, all clinical trials testing small
molecule, broad-spectrum MMP inhibitors in a range of cancer
types and stages, to date, have failed to improve clinical outcomes
and resulted in major musculoskeletal toxicity in many cases. This
field is advancing tremendously, however, with the development
of many small molecule inhibitors and antibodies targeting
specific domains of particular tumour-promoting MMPs, and
improved targeting of natural MMP inhibitors, such as the tissue
inhibitors of metalloproteinases (TIMPs). This topic is extensively
reviewed in ref. 78 Recent clinical trials combining gemcitabine
with the SMO inhibitor, vismodegib, have also been underway in
patients with metastatic PDAC, despite the preclinical evidence
suggesting Hh-driven PDAC CAFs are also tumour suppressors;9
fibrosis was reduced in 45.4% of patients in a pilot trial, and no
toxicity was observed in a phase 1b/2 trial, but there was no
improved overall response rate or survival with dual therapy in
either trial.79,80 Perhaps these disappointments are due to the
non-selective ablation of Hh-driven, tumour-suppressing CAF
subtypes amongst the tumour-promoting subtypes. However, 3
of 12 patients with metastatic triple-negative breast cancer
treated with docetaxel and the SMO inhibitor Sonidegib in a
recent phase 1 clinical trial showed clinical benefit, with one
experiencing a complete response. The accompanying preclinical
data suggest that mechanistically these outcomes were due to
the downregulation of CSC markers.81 As more is learnt about the
heterogeneity of Hh-signalling CAFs, the aim is to target only
the pro-tumour subsets and ultimately lead to improved cancer
therapies.
Methods to inhibit CAF activation are also in development as
novel cancer therapeutics. The downregulation of the androgen
receptor (AR) in dermal fibroblasts was shown to induce early CAF
activation and enhance tumorigenicity of SCC and melanoma
cells. As such, this study suggested the use of bromodomain (BET)
inhibitors, such as JQ1, to restore AR expression. This resulted in
reduced CAF activity and prevented tumour growth in a
melanoma mouse model.82 Compounds such as the synthetic
vitamin-D derivative, calcipotriol, have also been used to block the
TGF-β-mediated differentiation of pancreatic fibroblasts into CAFs,
decreasing inflammation and fibrosis and improving chemother-
apeutic responsiveness in mice with spontaneous PDAC.83
Similarly, the endogenous bioactive lipid lipoxin A4 (LXA4) was
used to inhibit Smad2/3 signalling in pancreatic fibroblasts to
ultimately retard murine pancreatic tumour growth.84 In other
approaches, the epigenetic machinery inducing CAF activation has
been targeted. Firstly, TGF-β-mediated CAF differentiation was
targeted by using Scriptaid to inhibit histone deacetylase.
Reduced fibroblast content and activity, impaired collective CAF-
tumour cell invasion and delayed melanoma growth in vivo
resulted.85 Secondly, targeting the RNA editor, Adenosine
Deaminase family acting on RNA (ADAR1), appears warranted in
CRC; ADAR1 is overexpressed in human CRC and leads to elevated
antizyme inhibitor 1 (AZIN1) RNA editing levels, which is correlated
with increased CAF marker expression and aggressive tumours.86
Reprogramming activated fibroblasts or CAFs back into their
dormant state is another strategy for impairing tumorigenesis.
miRNAs have attracted interest in this context, and in the case of
lung fibrosis, upregulation of the miR-19a-19b-20a sub-cluster was
observed during disease progression. This sub-cluster suppressed
TGF-β-induced fibroblast activation, suggesting that normal
fibroblasts attempt to stop their own activation.87 Upregulation
of the TGF-β pathway inhibitor, miR-145, was also observed in
TGF-β-induced and primary oral cancer CAFs. When normal oral
fibroblasts were transfected with miR-145 prior to TGF-β
treatment, their in vitro activation was impaired, and when
transfected following treatment, their quiescent phenotype was
rescued. Thus, it is again seen that normal fibroblasts may
inherently contain a negative feedback loop to protect against
CAF conversion.88 Another study demonstrated that CAFs within
human breast tumours had decreased levels of the tumour
suppressor miRNA, Let-7b, compared with their normal fibroblast
counterparts. Inhibition of Let-7b in these normal breast
fibroblasts increased their activation and capacity to induce
breast cancer cell EMT in vitro, and enhanced tumour growth in a
murine breast cancer model. The opposite was observed upon re-
expression of Let-7b in human breast CAFs, and the cancer-
promoting abilities of breast myofibroblasts were reduced.89
Pancreatic CAFs have also been reprogrammed towards quies-
cence via activation of the tumour-suppressor p53 by the Nutlin-
3a derivative RG7112, resulting in a reduction of murine
pancreatic desmoplasia.90 The combined inhibition of DNA
methyltransferase activity and Janus kinase (JAK) signalling also
resulted in the long-term phenotypical and molecular reversion of
activated CAFs to normal, resting fibroblasts, causing murine
breast tumours to become less invasive.91
Although some preclinical studies have demonstrated the
benefits of targeting CAFs alone, presumably the simultaneous
targeting of both the tumour and CAF compartments will
ultimately improve efficacy in clinical trials. Some preclinical
studies have targeted both the tumour and CAFs with one
therapeutic agent. One group designed a novel dendrimer
conjugated to the mTOR inhibitor rapamycin to successfully
inhibit mTOR signalling and VEGF expression in prostate cancer
cells and fibroblasts, and reduce fibroblast-mediated prostate
tumour progression and metastasis.92 Another group targeted
neuregulin (NRG1), which is highly expressed in the cancer cells
and CAFs of PDAC. Their NRG1 inhibitory antibody, 7E3, was able
to promote apoptosis in the pancreatic tumour cells and CAFs,
and inhibit the growth of the tumour.93 Other studies have
combined different CAF-targeting and tumour-targeting drugs to
investigate their dual anti-tumour efficacy. For example, compro-
mising the integrity of collagen fibres using nab-paclitaxel,
combined with gemcitabine, reduced the number of CAFs and
improved overall survival in a phase 3 clinical trial of pancreatic
cancer, compared with either agent alone.94,95 Similarly, in the
preclinical setting, only the dual administration of the chemother-
apeutic oxaliplatin with PT-100 increased mouse survival by
decreasing CAF content, colon tumour growth, angiogenesis and
pro-tumour immune cell recruitment.96 This is not always the
outcome, however, as PT-100 combined with cisplatin for stage IV
melanoma or with docetaxel for non-small-cell lung carcinoma
(NSCLC) did not show a therapeutic advantage in phase 2 human
trials.97,98 Other trials have attempted to reduce tumorigenesis by
disrupting the cross-talk between the cancer and CAFs. As an
example, HGF is predominantly produced by CAFs and activates
its cognate receptor, c-Met kinase, on tumour cells, promoting
tumorigenesis and chemoresistance via a variety of mechanisms
(reviewed in ref. 99). HGF and c-Met have both been targeted in
many preclinical and clinical trials; for example, inhibition of HGF
via a neutralising antibody or siRNA knockdown impaired gastric
tumour growth in mice,100 and the combination of gemcitabine
with the c-Met inhibitor, tivantinib, demonstrated early signs of
anti-tumour activity in various solid tumours in a phase 1 trial,
warranting a phase 2 trial.101 In recent times, many c-Met small
molecule inhibitors have been in development and they are
reviewed in ref. 102
There are many tumour-CAF co-targeting clinical trials currently
recruiting patients: for example, RO6874281 is a recombinant
fusion protein that targets an engineered, variant form of IL-2 to
human FAP+ cells, to stimulate a local immune response and
therefore improve anti-tumour immunity. It is currently being
combined with trastuzumab (for HER2+ breast cancers) or with the
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epidermal growth factor receptor (EGFR) inhibitor cetuximab (for
head and neck cancers) in phase 1 trials (NCT02627274), or with
the anti-PD-L1 antibody atezolizumab in a phase 2 trial
investigating advanced and/or metastatic solid tumours
(NCT03386721). The scientific community awaits the outcomes
of these, and other, tumour-CAF-targeted trials.
Using CAFs as a means of drug delivery
Another strategy for CAF-directed anti-cancer therapy involves the
skewing of CAFs towards a suppressive phenotype. However, to
the best of our knowledge, no studies have directly explored this
approach; the lack of specific biomarkers for CAFs and for their
tumour-promoting and tumour-suppressing phenotypes has
become a hindrance. However, one way to evade the issues
surrounding CAF heterogeneity (for now) involves the use of the
general CAF population as a drug delivery tool. A prodrug has
been designed to be cleaved, using the protease activity of FAP,
into the cytotoxic drug thapsigargin, and it produced a local
therapeutic response in mouse models of breast and prostate
cancer.103 MMPs have also been used to cleave MMP-sensitive
micelles encapsulating the chemotherapeutic drug docetaxel,
releasing it locally to reduce cervical cancer growth in mice.104
Moreover, nanoparticles containing plasmids encoding a secreted
form of the pro-apoptotic factor TRAIL (sTRAIL) have been non-
specifically targeted to CAFs, modifying them to express sTRAIL.
This approach killed nearly all of the local bladder and pancreatic
tumour cells and diminished CAF numbers, prolonging survival
and efficiently ameliorating metastasis in preclinical models.105
Leucine-rich-repeat-containing 15 (LRRC15)+ CAFs have also been
targeted using a LRRC15-antibody drug conjugate (ABBV-085) to
deliver the potent anti-mitotic drug monomethyl auristatin E
(MMAE) in PDX models of NSCLC-adenocarcinoma, osteocarci-
noma, breast cancer and glioblastoma, significantly reducing
tumour volume. Nevertheless, complete responses in these
models were only seen when combined with various types of
chemotherapy, radiation and immune therapy agents.106
Another approach still in its infancy uses CAFs and CAF-derived
factors as ecological traps, designed to mimic the normal niche to
attract disseminated cancer cells that are subsequently killed via
methods, such as TRAIL-induced apoptosis and trap-targeted
stereotactic radiation.107 However, this method involves surgical
implantation, creating a wound site that in itself was observed to
activate tissue-resident fibroblasts and attract more cancer
cells.107 One group was able to encapsulate live CAFs in
microparticles that could then be intraperitoneally injected,
without wounding. The CAF-derived ECM surface of the beads
selectively captured disseminated cells from different tumour
origins, and the iron oxide nanoparticles incorporated into the
bead surface allowed for magnetic retrieval of the microparticles.
This technique was able to prolong mouse survival by delaying
peritoneal metastasis.107
CAFs as prognostic tools
The differential expression of specific genes in the tumour stroma,
compared with the normal stroma of the same tissue, generates
expression signatures that can offer prognostic clues in many
different types of cancers. One of the first studies to recognise the
prognostic relevance of the tumour stroma to survival and
recurrence, in breast cancer patients, identified a 26-gene
‘stroma-derived prognostic predictor’.108 This signature, however,
was not specific to CAFs but to all cells in the tumour stroma.
Other studies have since derived prognostic gene signatures from
the CAF population specifically, for example in CRC,5 NSCLC109 and
hepatocellular carcinoma.110 However, the CAF-associated signa-
tures identified in these studies do not overlap; for example, the
CRC 4-gene signature includes FAP and CALD1 (the gene encoding
caldesmon 1),5 the 11-gene NSCLC signature includes THBS2 (the
gene encoding thrombospondin 2) and CLU (the gene encoding
clusterin),109 and the 12-marker liver cancer panel includes
fibroblast growth factor 5 (FGF5) and MMP1.110 Again, hetero-
geneity is to blame for the lack of a uniform CAF-associated
prognostic gene signature, and it may be that every different type
of cancer has its own specific predictor. One group has also found
a CAF-associated gene signature that predicts chemotherapy
resistance in the neoadjuvant setting for breast cancer, based on
the differential expression of 50 genes, including DCN (the gene
encoding decorin), COL1A2 (the gene encoding collagen type
1α2), FAP, CALD1 and THBS2.111In addition, the presence of CD146-
expressing CAFs predicts tamoxifen sensitivity and better treat-
ment outcome in patients with oestrogen receptor-positive (ER+)
breast cancer, as they maintain ER expression (unlike CD146-null
CAFs).112
Tumour and CAF data can be obtained from the blood and
peritoneal fluid, and sequential liquid biopsy samples allow the
dynamic monitoring of these cells during cancer progression. This
technique was originally used to detect disseminated cancer cells,
which were indicative of increased recurrence and poorer survival
and therefore served as prognostic, metastatic markers.107 However,
this technology was subsequently enriched to detect circulating
CAFs, demonstrating that CAFs were present in 88% of breast cancer
patients with metastases, 23% of patients with localised disease and
0% of healthy donors.113 Moreover, in oesophageal cancer, ADAM12
is the serum-borne marker for IL-6+ CAFs, and its presence predicts
poor response to neoadjuvant chemoradiation.46
CAF MARKERS AND HETEROGENEITY
Historically, research has underestimated the complexity of CAF
heterogeneity and studies have used the entire, mixed, CAF
population to draw general conclusions, an approach that is likely
to have resulted in observational variability and ultimately
enhanced confusion in the field. As we come to appreciate the
complexity of CAFs, studies are now attempting to single out
specific CAF subtypes, predominantly targeting the two most
common types— either α-SMA+ or FAP+ CAFs. But, even this
approach has had variable results, and their co-expression is also
debatable. One study demonstrated that they define completely
different CAF subsets, at least in CRC, with α-SMA associating with
other activated fibroblast markers such as transgelin (TAGLN) and
platelet-derived growth factor subunit A (PDGFA), whilst FAP
associated with other markers, including DCN and COL1A2.10 It is
worth noting that this was the first comprehensive study that
attempted to define human CAF subsets, using single-cell
sequencing. Another study defined α-SMAHighFAP+ pancreatic
CAFs as a myofibroblastic, active subtype responsive to TGF-β,
while the remaining α-SMALow CAFs were shown to secrete
inflammatory mediators such as IL-6 that promoted the growth
and proliferation of patient-derived PDAC organoids. These two
CAF subtypes were mutually exclusive, but reversible in different
culture conditions.114 Furthermore, another study that defined
four breast CAF subsets, based on their expression of α-SMA, FAP,
FSP1, PDGFRβ and CD29, demonstrated that α-SMAHighFAPHigh
CAFs were associated with an immune-suppressive environment,
enhancing Treg cells via CXCL12 secretion. The α-SMAHighFAPNeg
CAF subset was devoid of these properties.115 These last two
studies are some of the first to examine the potential functional
roles of different CAF populations in pancreatic and breast cancer,
respectively, yet the α-SMA+FAP+ CAF subset they both identified
had slightly different properties. Similar CAF subtypes may
therefore have unique roles in each tissue type, adding an extra
layer of complexity. There are also differences in CAF marker
expression between tissues; for example, 43.5% of α-SMA+
fibroblasts co-expressed FSP1 in pancreatic cancer, but this
overlap was reduced to 10.9% in breast cancer.11 CAFs may
therefore be further regulated by other unknown, tissue-specific
factors.
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Other studies have attempted to define CAF heterogeneity, not
based on α-SMA and FAP expression. Bartoschek et al.116 were
able to define three distinct populations of breast cancer CAFs
from a mouse model, which was confirmed in patients; vascular
CAFs (vCAFs) were Nidogen2+, matrix-related CAFs (mCAFs) were
Pdgfrα+ and developmental CAFs (dCAFs) were Pdgfrβ−Scrg1+.
αSMA and FAP expression did not segregate with these
populations. The presence of vCAFs and mCAFs correlated with
metastatic dissemination, and the mCAF signature additionally
correlated to a treatment-predictive stromal signature in breast
cancer. Each subset could be spatially separated and this was
linked to different origins; vCAFs from perivascular cells, mCAFs
from resident fibroblasts and dCAFs from tumour cells that had
undergone EMT.116 The heterogeneity of CAFs is understandable
given different source populations in different locations. Another
example of spatially demarcated CAFs was demonstrated by
Cremasco et al.117 in a mouse model of immune-excluded breast
cancer, where FAP+PDPN+ CAFs were localised around the
tumour edge and in close contact with T cells, while FAP+PDPN−
‘cancer-associated pericytes’ (CAPs) surrounded vessels. Interest-
ingly, CAFs were enriched in TGF-β signalling and fibrosis and
produced nitric oxide to suppress T-cell proliferation; CAPs were
not immunosuppressive.117 Moreover, Biffi et al.118 demonstrated
that myofibroblastic CAFs (myCAFs) were found adjacent to PDAC
tumours, while inflammatory CAFs (iCAFs) were preferentially
localised in the dense PDAC stroma. This study demonstrated
another concept alluded to above, that tumours can influence CAF
activation and as a result also CAF heterogeneity; PDAC tumour-
derived IL-1 steered CAFs towards an iCAF phenotype, while TGF-β
biased towards myCAFs. CAFs in different locations could there-
fore have been exposed to different tumour ligands, influencing
their phenotype. TGF-β was also shown to convert iCAFs into
myCAFs, via antagonism of the JAK/STAT pathway and down-
regulation of IL-1R1 expression.118 The presence of interconvertible
myCAFs and iCAFs in PDAC is supported by Ohlund et al.114 Biffi
et al.118 therefore suggest drug combinations targeting both iCAFs
and myCAFs, to decrease tumour-promoting inflammation and
deplete the dense stroma impeding drug delivery. In another
study, Neuzillet et al.119 proposed the ‘pCAFassigner' classification
system to segregate their three defined human-derived PDAC CAF
subtypes based on the expression of periostin (POSTN), myosin-11
(MYH11) and PDPN. Tumour-conditioned medium was shown to
induce two of the three CAF subtypes in pancreatic stellate cells
in vitro, suggesting tumours can influence dynamic CAF states.119 It
also appears that the cancer stage can influence the dominating
CAF phenotype, via cancer-derived exosomes, particularly in CRC;
early-stage CRC exosomes promoted highly proliferative and
angiogenic CAFs, while late-stage exosomes from metastatic CRC
lines induced highly invasive CAFs.120
CONCLUSION
Tumours and their local microenvironment form a complex
ecosystem that can ultimately promote cancer progression. It
has now become widely accepted that CAFs can have a dual role
in tumorigenesis, owing to their heterogeneity; they can either
promote cancer via induction of an inflammatory, immune-
suppressive, angiogenic, energy-rich, invasive and metastatic
environment, or suppress cancer via predominantly unknown
mechanisms (Fig. 1). It might be that fibroblasts begin as a
tumour-suppressive cell type, but as the tumour develops it
begins to influence the environment and transforms these
fibroblasts into pro-tumoural factories. It is therefore conceivable
that fibroblasts act as both heroes and villains.
As different CAF expression profiles may define their role in
tumorigenesis, CAF molecular marker combinations must be
further refined to assist in the classification of pro- and anti-
tumour subsets in different tissues. This will provide us with better
prognostic CAF biomarkers and more specific avenues for CAF-
directed cancer treatments, allowing us to precisely target the
tumour-promoting subtypes and CAF-derived factors or skew the
CAF phenotype away from tumour promotion, or prevent CAF
activation altogether (Fig. 2). These novel strategies can then be
combined with other tumour-targeting drugs to ultimately
improve treatment efficacy and patient survival.
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Fig. 2 CAF-directed cancer therapies. Outlined are several preclinical and clinical approaches aimed at targeting CAFs in an attempt to
impede tumorigenesis. Ideally, for full efficacy, these strategies will be used in conjunction with drugs that target tumours
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